Aerpio Pharmaceuticals, Inc. (ARPO)


-0.02 (-0.90%)
Symbol ARPO
Price $2.2
Beta 1.647
Volume Avg. 0.40M
Market Cap 104.853M
Shares () -
52 Week Range 2.16-49.79975
1y Target Est -
DCF Unlevered ARPO DCF ->
DCF Levered ARPO LDCF ->
Operating Margin -
Debt / Equity -
P/E -
P/B -


Consensus EPS

Upgrades & Downgrades

Latest ARPO news

Nasdaq Capital Market

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.